Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy

Trial Profile

Safety and Efficacy Study of Gene Therapy for The Treatment of Leber's Hereditary Optic Neuropathy

Active, no longer recruiting
Phase of Trial: Phase II/III

Latest Information Update: 04 May 2018

At a glance

  • Drugs RAAV2 ND4 (Primary)
  • Indications Leber's hereditary optic atrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Apr 2018 Planned primary completion date changed from 30 Dec 2018 to 30 Jun 2019.
    • 28 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 26 Dec 2017 Design keyword has changed from double-blind to open label.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top